Objective To explore the clinical effects of intravitreal injection of conbercept in the treatment of choroidal neovascularization (CNV).Methods A total of 109 patients with CNV were selected and randomly divided into two groups,Ranibizumab group (n =56),in which the patients were treated with intravitreal injection of ranibizumab,and conbercept group (n =53),in which the patients were treated with intravitreal injection of Conbercept.The best corrected visual acuity (BCVA),central retinal thickness (CRT),and intraocular pressure (IOP) changes and adverse reactions between the two groups before and after the treatment were compared and the curative effects of conbercept were evaluated.Results One month after the treatment,there was no significant difference in the proportion of improvement of the patients' visual acuity between the two groups (P ＞ 0.05);two months later,the proportions of improvement of the patients' visual acuity in the two groups were significantly higher than those one month after the treatment (P ＜ 0.05),but the comparison between the two groups showed no statistically significant difference (P ＞ 0.05).Compared with the situation before the treatment,the average logarithmic visual acuity in the two groups one month and two months later was significantly improved and the CRT values were significantly lower(P ＜ 0.05),but there was no significant difference between the two groups (P ＞ 0.05).Before and after the treatment,there was no significant change in IOP in the two groups(P ＞ 0.05).During the follow-up visit of six months,there was no significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05).According to the re-examination one month after the surgery,there was no significant difference in the rate of recurrence between the two groups (P ＞ 0.05);the cost of conbercept for the treatment was significantly lower than that of ranibizumab.Conclusion The short-term curative effects and adverse effects of conbercept on CNV are equivalent to those of ranibizumab,but the price is lower,so it is worthy of clinical promotion.
国家科技期刊平台
NSTL
维普
万方数据
